| Similar Articles |
|---|
 |
Bio-IT World
February 11, 2005
Robert M. Frederickson |
Genomics Drives New Crop of IVDs In vitro diagnostic microarrays are an important tool in oncology. The Affymetrix GeneChip System 3000Dx (GCS 3000Dx) was the first microarray instrument to be cleared by the FDA for IVD use.   |
HHMI Bulletin
May 2012
Sarah C. P. Williams |
Opening the Floodgates Researchers are using exome sequencing -- zeroing in on the genes that encode proteins -- to explore the biology of certain diseases. |
Bio-IT World
Jul/Aug 2006
Kate McDonald |
The Next Generation in Sequencing Is SOLiD Applied Biosystems has completed the acquisition of genetic analysis company Agencourt Personal Genomics for $120 million, and hopes to bring the company's novel next-generation sequencing technology to market next year. |
Bio-IT World
October 2006
Kevin Davies |
Cracking the Cancer Genome Regardless of which technologies win out, or which centers win the lucrative sequencing contracts, the Cancer Genome Atlas has a sublime medical and scientific importance, underscored by the latest findings from Hopkins. |
InternetNews
June 13, 2005
Clint Boulton |
IBM Delivers Baby Brother For Blue Gene IBM released a companion to its fastest supercomputer that boasts a top speed of 91.29 teraflops |
Chemistry World
February 25, 2015
Rebecca Trager |
US opens up home DNA screening The US Food and Drug Administration has, for the first time, authorized a genetic test to be sold directly to consumers. The agency plans to ease the regulatory path for similar screening tests. |
The Motley Fool
August 20, 2011
Luke Timmerman |
Seattle Genetics Wins FDA Approval of First Drug FDA gives a quick turnaround on the new treatment for lymphomas. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Bio-IT World
February 11, 2005
Kevin Davies |
The Galileo Code In searching 400 years of French-Canadian history for genetic clues to diseases among Quebec's founding population, Genizon BioSciences -- formerly Galileo Genomics -- is rapidly becoming the bio-IT company du jour. |
Bio-IT World
May 2006
Kevin Davies |
Interpreting Genes and Genomes From microarrays to sequencing technology, molecular diagnostics to the interactome, this year's Bio-IT World Conference showcased exciting advances in genome technology applications, in which software analysis and data management play critical roles. |
American Journal of Nursing
August 2010
Lomas & Fowler |
Parents and Children with Cystic Fibrosis A survey was conducted to estimate how many adult patients with cystic fibrosis who receive care at centers accredited by the Cystic Fibrosis Foundation also have biological children with the disease. |
BusinessWeek
October 23, 2008
John Carey |
Reading the Entire Genetic Code Pioneers such as 23andMe and Navigenics use snips of genes to make medical predictions. Now new tools from more start-ups are on the horizon. |
The Motley Fool
August 12, 2009
Brian Orelli |
The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing. |
Chemistry World
June 9, 2015
Phillip Broadwith |
Vertex nabs rights to cystic fibrosis molecules Specialist pharmaceutical firm Vertex has struck a development deal with start-up Parion Sciences to develop Parion's investigational drug candidates for respiratory diseases, including cystic fibrosis. |
Bio-IT World
October 2005
Dennis A. Gilbert |
The DNA Sequencing Race: From Sprint to Marathon To create faster, cheaper, and better solutions for DNA analysis, we must remain committed to improving both current and new sequencing technologies. Research that just a short while ago might have been considered too complex, too expensive, or just inconceivable is now well within our grasp. |
Chemistry World
December 4, 2014
Anthony King |
Cystic Fibrosis Foundation sells drug royalty rights for $3.3bn The Cystic Fibrosis Foundation has sold royalty rights to treatments developed with support from its 'venture philanthropy' model. |
The Motley Fool
June 14, 2010
Bruce Bigelow |
Genetic Testing Companies in San Diego, Boston, and San Francisco Studying FDA Letters The letters notify the companies that genome-sequencing tests they offer to consumers are medical devices that require the agency's approval. |
Bio-IT World
March 8, 2005
Kevin Davies |
Evolution of New Genes Studied EMBL researchers use comparative genomic analysis to identify new primate-specific gene family. |
Bio-IT World
July 2005
Kevin Davies |
MicroRNAs Alter Cancer Scene MicroRNAs (miRNAs) are tiny RNA molecules of about two-dozen nucleotides in length. While there have been hints that miRNAs might be associated with certain cancers, the new studies unequivocally show that to be the case. |
Food Engineering
October 29, 2008 |
Free food safety kit for food industry employees FDA, in collaboration with the Centers for Disease Control and Prevention and the US Department of Agriculture, launched its food defense awareness training kit for first-line food industry employees. |
Pharmaceutical Executive
September 1, 2010 |
The Testing of the Tests FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development. |
Salon.com
May 1, 2000
Arthur Allen |
Listening to DNA The genome project is getting the buzz. But the real breakthroughs may come from labs out of the limelight, like Gene Logic. |
The Motley Fool
January 3, 2012
Alex Planes |
Another Entry in the Genome Patent Rumble There's a whole lot of lawsuits going on. |
Bio-IT World
January 13, 2003
Julia Boguslavsky |
A Sequel to the Sequence The all-but-complete human genome sequence is not only an indispensable tool for biomedical research but also a major influence on the types of instrumentation researchers will invest in. |
| Knowledge@Wharton |
From Skin Creams to Life Insurance to Medical Care, Biosciences Are the New Frontier of Business Opportunity Research in the biological sciences holds the potential for breakthroughs that could transform the world. But scientific advances also can be baffling and more than a little intimidating, especially for business people... |
Bio-IT World
June 17, 2004
Michael A. Goldman |
A Hip Approach to Gene Hunting IntegraGen defines the genetic blueprint of complex human diseases and delivers validated disease markers and therapeutic targets for a better diagnosis and a causal treatment of common diseases, based on its unique genomic analysis expertise. |
Chemistry World
August 22, 2014
Phillip Broadwith |
Illumina targets cancer diagnostics Genetic sequencing heavyweight Illumina has partnered with three major pharmaceutical firms in a bid to develop a universal sequencing-based oncology test system. |
Bio-IT World
September 9, 2002
Malorye Branca |
The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems. |
Bio-IT World
January 21, 2005
Kevin Davies |
Allen Brain Institute Debuts 'Google for Gene Activity' The Allen Institute for Brain Science has released its first set of gene-expression data in the brain for nearly 2,000 mouse genes. The data will have important relevance for the study of brain function, disease, and the role of genes in governing human behavior. |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
InternetNews
June 6, 2005
Clint Boulton |
Your Brain on Blue Gene IBM researchers and scientists in Switzerland will create a digital 3D model of the brain with Blue Gene. |
Salon.com
December 19, 2000
Carolyn McConnell |
"The Century of the Gene" by Evelyn Fox Keller A new book argues that there may be no such thing as a gene. At least, it has proved very difficult to isolate a discrete physical item that can do the work our notion of the gene does... |
Bio-IT World
April 15, 2003
Malorye Branca |
Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease? |
Bio-IT World
December 10, 2002 |
Craig Venter Unvarnished (part II) The former Celera CEO covers privacy, ESTs, and his new research institutes. |
The Motley Fool
July 21, 2010
Ryan McBride |
Eli Lilly Pays up to $380M for Alnara Pharma Indianapolis-based Lilly is paying $180 million upfront for all of Alnara's shares, and shareholders are eligible for as much as $200 million in additional payments depending on whether certain regulatory and commercial milestones are met. |
